BRCA1 and breast carcinoma: These data underscore that although testing for the three BRCA1/2 AJ founder mutations has 90% sensitivity for clinically important breast cancer risk variants in those of full AJ descent, it has limited utility as a screening tool for identifying HBOC syndrome, especially among those of non-AJ or partial AJ descent.